Pegylated Nanoparticles
Pegylated Nanoparticles - Related Videos
08:04
Evaluation of Nanoparticle Uptake in Tumors in Real Time Using Intravital Imaging
0 Views •
Cited by 51 •
2011
We present a novel approach to quantify nanoparticle localization in the vasculature of human xenografted tumors using dynamic, real-time intravital imaging in an avian embryo model.
14:04
Viral Nanoparticles for In vivo Tumor Imaging
0 Views •
Cited by 45 •
2012
Plant viral nanoparticles (VNPs) are promising platforms for applications in biomedicine. Here, we describe the procedures for plant VNP propagation, purification, characterization, and bioconjugation. Finally, we show the application of VNPs for tumor homing and imaging using a mouse xenograft model and fluorescence imaging.
09:24
Synthesis, Hemoglobin Encapsulation and Biorthogonal PEGylation in Hierarchically Porous UiO-66 Nanoparticles for Oxygen Delivery Applications
0 Views •
2026
This protocol details the synthesis, hemoglobin encapsulation, and surface PEGylation of hierarchically porous UiO-66 nanoparticles designed for oxygen delivery. The procedure combines defect engineering with strain-promoted biorthogonal conjugation to generate highly permeable and physiologically stable carriers suitable for biomedical applications.
08:35
Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
0 Views •
Cited by 28 •
2012
Type B gelatin-based engineered nanovectors system (GENS) was developed for systemic gene delivery and transfection in the treatment of pancreatic cancer. By modification with epidermal growth factor receptor (EGFR) specific peptide on the surface of nanparticles, they could target on EGFR receptor and release plasmid under reducing environment, such as high intracellular glutathione concentrations.
09:23
Harmonic Nanoparticles for Regenerative Research
0 Views •
Cited by 1 •
2014
Protocol details are provided for in vitro labeling human embryonic stem cells with second harmonic generating nanoparticles. Methodologies for hESC investigation by multi-photon microscopy and their differentiation into cardiac clusters are also presented.
FAQs
PEG creates a hydrated, sterically protective surface around the particle. This water-rich barrier can reduce the adsorption of proteins onto the nanoparticle surface, which changes how biological systems interact with the carrier. By limiting these surface interactions, pegylation can support greater colloidal stability and help the therapeutic particle behave more consistently after administration.
Reduced protein adsorption may decrease recognition by the mononuclear phagocyte system, a group of cells involved in clearing particulate material from the body. This reduced recognition can slow removal from the circulation and potentially extend circulation time. The resulting exposure profile may improve opportunities for the nanoparticle to transport its therapeutic payload before clearance.
Nanoparticle size, surface properties, and drug-release design all influence biodistribution, meaning where the system travels in the body. These features also affect cellular uptake and the timing of therapeutic availability. Consequently, changing the particle architecture can alter how much payload reaches relevant tissues, how cells interact with the carrier, and how the treatment performs.
The PEG component can be applied as a coating or chemically linked to the nanoparticle. The resulting system is then designed around the intended therapeutic cargo and its release behavior. This approach allows researchers to combine surface protection with transport of poorly soluble drugs, nucleic acids, or other therapeutics while adjusting properties that affect stability and biological performance.
They are useful when a therapy would benefit from improved transport, altered pharmacokinetics, or greater tolerability. Their design can support delivery of poorly soluble drugs, nucleic acids, and other therapeutic materials. In medicine, the platform is therefore relevant when controlling particle behavior, payload availability, and circulation is important to the intended treatment outcome.
Evaluation should consider pharmacokinetics, biodistribution, cellular uptake, drug release, efficacy, and tolerability. These measures show whether the particle remains sufficiently stable, reaches relevant biological locations, releases its payload appropriately, and improves therapeutic performance. Examining the outcomes together is important because changes in surface properties or size can affect several aspects of behavior at once.